WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Hometown of Laura Ingalls Wilder set for a growth spurt
Rory McIlroy insists he is 'way better' than his last Major win in 2014
Future of Baby Reindeer 'confirmed' after fans of the hit Netflix drama begged for second series
Migrants storm onto California beach after landing in boat as stunned crowds look on
Day care costs: With Congress reducing support, states step in to help families
A monarchy reform activist in Thailand dies in detention after a monthslong hunger strike
Spain withdraws its ambassador to Argentina over comments made by President Milei
Investigators continue search for the hit
Cristiano Ronaldo to lead Portugal into record sixth European Championship
Padma Lakshmi, Halsey, Saweetie and Lucy Liu dazzle with high